Study of blood samples in skin cancer patients
Liquid Biomarker Study in Melanoma and Non-Melanoma Skin Cancers
This study is testing blood samples from skin cancer patients to see if certain markers can help predict how well their treatment is working.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 20 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Wisconsin, Madison Academic / other |
| Locations | 1 site (Madison, Wisconsin) |
| Trial ID | NCT06608511 on ClinicalTrials.gov |
What this trial studies
This observational study aims to analyze blood samples from participants with melanoma and non-melanoma skin cancers to identify potential biomarkers for predicting progression-free survival. Participants undergoing standard treatment will provide blood samples, which will be assessed for circulating tumor cells, circulating tumor DNA, and tumor-derived exosomes. The study seeks to correlate these blood-based signatures with clinical outcomes to enhance prognostic and monitoring capabilities in skin cancer management.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with a confirmed diagnosis of melanoma or non-melanoma skin cancer.
Not a fit: Patients who are part of vulnerable populations, such as pregnant women or children, will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved methods for predicting treatment outcomes in skin cancer patients.
How similar studies have performed: Other studies have shown promise in using blood-based biomarkers for cancer prognosis, suggesting this approach may be viable.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥18 years. * Participants must meet at least one of the following criteria: * Finding suspicious of melanoma or non-melanoma skin cancer based on clinical, radiographic, or laboratory findings. Non-melanoma skin cancers include: basal cell carcinoma, cutaneous squamous cell carcinoma, and Merkel cell carcinoma. * A confirmed diagnosis of melanoma or non-melanoma skin cancer. Exclusion Criteria: * Vulnerable populations, including pregnant women, those who lack consent capacity, the mentally ill, prisoners, cognitively impaired persons, children (age \<18), and UW employees that report to the investigator(s) or to study team members. * Not suitable for study participation due to other reasons at the discretion of the investigators.
Where this trial is running
Madison, Wisconsin
- University of Wisconsin — Madison, Wisconsin, United States (Recruiting)
Study contacts
- Principal investigator: Vincent Ma, MD — University of Wisconsin, Madison
- Study coordinator: Cancer Connect
- Email: clinicaltrials@cancer.wisc.edu
- Phone: 800-622-8922
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.